| 2.44 0.14 (6.09%) | 05-05 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 3.1 | 1-year : | 3.45 |
| Resists | First : | 2.65 | Second : | 2.95 |
| Pivot price | 2.36  |
|||
| Supports | First : | 2.17 | Second : | 1.8 |
| MAs | MA(5) : | 2.34 |
MA(20) : | 2.4 |
| MA(100) : | 2.18 |
MA(250) : | 1.4 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 38.7 |
D(3) : | 32.6 |
| RSI | RSI(14): 49.5 |
|||
| 52-week | High : | 3.61 | Low : | 0.49 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ CNTX ] has closed below upper band by 25.4%. Bollinger Bands are 53.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 4 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 2.45 - 2.46 | 2.46 - 2.47 |
| Low: | 2.28 - 2.29 | 2.29 - 2.3 |
| Close: | 2.42 - 2.44 | 2.44 - 2.46 |
Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of cancer for women in the United States. Its lead product candidate is onapristone extended release (ONA-XR), a potent and selective antagonist of the progesterone receptor that is linked to resistance for various classes of cancer therapeutics, such as anti-estrogen therapies across female hormone-dependent cancers. The company is also developing CLDN6xCD3 bsAb, an anti-CD3 x anti-Claudin 6 antigen bispecific monoclonal antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of an anti-claudin 6 bispecific monoclonal antibody for gynaecologic cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.
Fri, 01 May 2026
Context Therapeutics (NASDAQ: CNTX) ends charter suit with $850K mootness fee - Stock Titan
Wed, 22 Apr 2026
Piper Sandler Reaffirms Their Buy Rating on Context Therapeutics (CNTX) - The Globe and Mail
Fri, 17 Apr 2026
Context Therapeutics (CNTX) seeks 100M-share charter increase ahead of June meeting - Stock Titan
Thu, 02 Apr 2026
Context Therapeutics' CTIM-76 Wins FDA Fast Track; Phase 1a Interim Data Due June 2026 - TradingView
Thu, 02 Apr 2026
Context Therapeutics Announces CTIM-76 Receives FDA Fast Track Designation for the Treatment of Platinum-Resistant Ovarian Cancer - ChartMill
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 92 (M) |
| Shares Float | 43 (M) |
| Held by Insiders | 1.1 (%) |
| Held by Institutions | 76.8 (%) |
| Shares Short | 864 (K) |
| Shares Short P.Month | 1,290 (K) |
| EPS | -0.38 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.66 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -29.8 % |
| Return on Equity (ttm) | -46.4 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.44 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -26 (M) |
| Levered Free Cash Flow | -19 (M) |
| PE Ratio | -6.43 |
| PEG Ratio | 0 |
| Price to Book value | 3.69 |
| Price to Sales | 0 |
| Price to Cash Flow | -8.5 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|